Health News Today banner for November 8, 2026 highlighting the Lp(a) heart drug trial results, FDA gene therapy safety investigation, and Medicare Part D GLP-1 coverage gap

Health News Today, Nov 8: Lp(a) Trial, FDA Alert, Medicare

Mr Steady Natural Health

2 days ago

5 min read

Updated: 42 minutes ago

In health news today, late-breaking cardiology data, a federal safety investigation, and major clinical and policy studies reshape key conversations around heart risk, prescription coverage, and healthy aging for Americans over 45. Researchers at the American Heart Association Scientific Sessions reported an unexpected setback for a closely watched cholesterol-particle drug, while federal regulators opened a tumor-risk review of spinal muscular atrophy gene therapies. Meanwhile, newly published analyses revealed stark Medicare Part D coverage gaps for non-diabetes GLP-1 drugs, reassuring dementia findings for common overactive bladder prescriptions, and encouraging immune responses from an experimental pancreatic cancer vaccine.

Summary chart of today's 5 health headlines on November 8, 2026 comparing what happened and what it means for adults over 45

Lp(a) Heart Drug Pelacarsen Fails Major Phase 3 Trial

An experimental medication widely expected to become the first targeted therapy for elevated lipoprotein(a)—an inherited blood fat linked to heart attacks and strokes—failed to reduce cardiovascular events in a landmark study, CNN Health reported November 7. Presented Saturday at the American Heart Association Scientific Sessions in Chicago by Cleveland Clinic preventive cardiologist Dr. Steven Nissen, the seven-year Phase 3 trial tracked 8,350 adults with high Lp(a) and a prior heart attack or stroke. Although Novartis' drug pelacarsen lowered sticky, clot-promoting Lp(a) particles by roughly 70% to 80%, patients receiving the injections fared no better than placebo recipients on heart-related deaths, nonfatal heart attacks, strokes, or urgent artery procedures over nearly five years. Because participants already kept LDL cholesterol tightly controlled on statins, investigators noted that future Lp(a) therapies may require deeper reductions or earlier preventive use alongside everyday cardiovascular habits.

What it means for you: About one in five adults carries elevated Lp(a) from birth, and a one-time blood test can still help clarify your overall cardiovascular risk profile. If your Lp(a) is high, talk with your doctor or cardiologist about managing modifiable factors such as LDL cholesterol, blood pressure, weight, and regular physical activity.

FDA Investigates Tumor Risk Linked to SMA Gene Therapies

Federal regulators announced late November 6 that they are investigating a serious risk of tumor formation, including cancer, in patients treated with Zolgensma for spinal muscular atrophy, according to an official FDA safety communication. The agency received postmarketing adverse event reports involving tumors of the nervous system, spinal region, and kidney, including three cases tied to abnormal activation of the GLI1 oncogene. Molecular testing in two cases confirmed that DNA from Zolgensma's adeno-associated virus (AAV) delivery vector integrated into patient cells near GLI1. Regulators stated that the potential neoplasia risk applies to both intravenous Zolgensma, used in children under age two, and intrathecal Itvisma, cleared in November 2025 for adults and children aged two and older because both therapies share the same genetic construct. While noting that overall benefits still outweigh risks for authorized uses, the agency is reviewing product labeling and monitoring similar AAV gene therapy programs.

What it means for you: Adults living with spinal muscular atrophy, clinical trial participants, and grandparents or caregivers of treated children should watch for new or unexplained symptoms during long-term follow-up. Speak with your neurologist or care team before making any care decisions, and ask what routine monitoring applies to past or planned gene therapy.

Study Finds Steep Medicare Part D Gap for Non-Diabetes GLP-1s

Despite federal clearances allowing Wegovy and Zepbound to address cardiovascular risk, metabolic liver fibrosis, and obstructive sleep apnea, routine Medicare prescription plans rarely cover either medication outside diabetes, according to a Health Affairs Scholar analysis indexed November 6 on NIH PubMed Central. Researchers at the University of Georgia and the USC Schaeffer Institute reviewed federal formulary files from 2024 through 2026 across thousands of standalone Part D and Medicare Advantage prescription plans. Not a single standalone Part D plan listed Wegovy or Zepbound for non-diabetes uses during the three-year span, while Medicare Advantage plan coverage peaked at 1.9% in 2025 before dropping to 0.9%—reaching just 0.7% of enrollees—in 2026. Only 19% of 2025 plans carrying the drugs kept them on 2026 formularies, and county-level access was lowest where coronary heart disease rates were highest.

What it means for you: With Medicare Open Enrollment running through December 7, never assume a Part D or Medicare Advantage plan covers GLP-1 prescriptions for heart, liver, or sleep apnea conditions. Check each 2027 plan formulary carefully and ask your doctor or pharmacist about prior-authorization rules or formulary exception pathways before switching coverage.

830,000-Adult Study Rethinks Bladder Drugs and Dementia Risk

Older overactive bladder medications known as anticholinergics did not carry a higher long-term risk of dementia than newer beta-3 agonist prescriptions in a massive U.S. health-record study indexed November 6 on NIH PubMed. Published in JAMA Network Open, researchers at University Hospitals Cleveland Medical Center analyzed Epic Cosmos electronic records for 830,393 adults aged 40 to 90—with a median age of 67—who started bladder treatment between 2012 and 2025 without prior dementia. Over follow-up, weighted 10-year dementia incidence was 18.1% among patients prescribed older anticholinergics such as oxybutynin, tolterodine, or solifenacin, compared with 20.0% among those started on newer beta-3 agonists mirabegron or vibegron, and longer anticholinergic use did not raise dementia rates. Investigators concluded that earlier observational warnings likely reflected underlying neurological vulnerability rather than a direct long-term drug effect.

What it means for you: If you take bladder control medication, these findings offer reassurance about long-term dementia fears, though anticholinergics can still cause short-term side effects like dry mouth, constipation, or grogginess in older adults. Review your full medication list with your doctor or pharmacist before starting, switching, or stopping any urinary prescription.

Pancreatic Cancer Vaccine Triggers 99% Immune Response in Trial

An experimental "off-the-shelf" vaccine designed to target common KRAS gene mutations sparked robust immune activity in almost every recipient after pancreatic cancer surgery, Medical News Today reported November 7. In the randomized Phase 2 AMPLIFY-7P trial of 144 adults with stage 1 to 3 pancreatic ductal adenocarcinoma who had completed surgery and chemotherapy, 96 patients received the lymph-node-targeted vaccine camupepimut while 48 underwent standard observation. Nearly 99% of vaccinated participants mounted KRAS-specific T-cell responses, and more than 82% showed at least a ninefold jump in T-cell activity with no treatment-related deaths or dropouts. Although overall median disease-free survival—23.8 months versus 21.2 months—did not reach statistical significance across the full cohort, patients without detectable circulating tumor DNA at baseline showed stronger signals, prompting plans for a larger Phase 3 study.

What it means for you: Pancreatic cancer most often affects adults over 55 and carries a high risk of returning after surgery, so camupepimut remains an investigational option rather than standard care. If you or a loved one are navigating pancreatic cancer treatment, ask an oncology specialist whether biomarker testing or clinical trials fit your care plan.

Related reading: yesterday's H1N1 flu and kratom briefing.

Related reading: November 9 FDA recall and BP news.

Related reading: latest GLP-1 vision warning update.